Wiley Matthew T.'s Form 4/A amendment
AmendedBioXcel Therapeutics, Inc. (BTAIQ) · filed Sep 17, 2024
- Accession no.
- 0001104659-24-100745
- Filed
- Sep 17, 2024
- Trade date
- Jun 15-17, 2024
- Filing delay
- 94 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Jun 18, 2024
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $307.44. It was filed 94 days after the trade.
This amendment replaces 0001104659-24-073003 (filed Jun 18, 2024).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wiley Matthew T.CIK 0001759703 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 15, 2024 | Common Stock | MOption exerciseAcquired | +750 | – | – | 3,742 | Direct | |
| Jun 17, 2024 | Common Stock | SSaleDisposed | −244 | $1.26 | −$307.44 | 3,498 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 15, 2024 | Common Stock | MOption exerciseDisposed | −750 | $0.00 | $0 | 8,250 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.